ACTEMRA (Tocilizumab) is a prescription monoclonal antibody used to treat inflammatory conditions such as rheumatoid arthritis (RA), giant cell arteritis (GCA), and cytokine release syndrome (CRS). It works by blocking the interleukin-6 (IL-6) receptor, reducing inflammation and immune system overactivity. This intravenous (IV) formulation is supplied in a single-dose vial for hospital or clinical administration.
